| Screening methods used to determine the anti-microbial properties of Aloe vera inner gel F Habeeb, E Shakir, F Bradbury, P Cameron, MR Taravati, AJ Drummond, ... Methods 42 (4), 315-320, 2007 | 293 | 2007 |
| Bacterial outer membrane vesicles and vaccine applications R Acevedo, S Fernández, C Zayas, A Acosta, ME Sarmiento, VA Ferro, ... Frontiers in immunology 5, 121, 2014 | 270 | 2014 |
| Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection JFS Mann, E Shakir, KC Carter, AB Mullen, J Alexander, VA Ferro Vaccine 27 (27), 3643-3649, 2009 | 204 | 2009 |
| In Vitro Susceptibilities of Shigella flexneri and Streptococcus pyogenes to Inner Gel of Aloe barbadensis Miller VA Ferro, F Bradbury, P Cameron, E Shakir, SR Rahman, WH Stimson Antimicrobial agents and chemotherapy 47 (3), 1137-1139, 2003 | 181 | 2003 |
| The effects of cardamonin on lipopolysaccharide‐induced inflammatory protein production and MAP kinase and NFκB signalling pathways in monocytes … S Hatziieremia, AI Gray, VA Ferro, A Paul, R Plevin British journal of pharmacology 149 (2), 188-198, 2006 | 168 | 2006 |
| Delivery systems: a vaccine strategy for overcoming mucosal tolerance? JFS Mann, R Acevedo, J Campo, O Pérez, VA Ferro Expert review of vaccines 8 (1), 103-112, 2009 | 113 | 2009 |
| Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity JFS Mann, HE Scales, E Shakir, J Alexander, KC Carter, AB Mullen, ... Methods 38 (2), 90-95, 2006 | 110 | 2006 |
| Choice and design of adjuvants for parenteral and mucosal vaccines HFJ Savelkoul, VA Ferro, MM Strioga, VEJC Schijns Vaccines 3 (1), 148-171, 2015 | 106 | 2015 |
| Determination of the potential bioavailability of plant microRNAs using a simulated human digestion process A Philip, VA Ferro, RJ Tate Molecular nutrition & food research 59 (10), 1962-1972, 2015 | 105 | 2015 |
| The inner gel component of Aloe vera suppresses bacterial-induced pro-inflammatory cytokines from human immune cells F Habeeb, G Stables, F Bradbury, S Nong, P Cameron, R Plevin, VA Ferro Methods 42 (4), 388-393, 2007 | 99 | 2007 |
| Optimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutinin JFS Mann, VA Ferro, AB Mullen, L Tetley, M Mullen, KC Carter, ... Vaccine 22 (19), 2425-2429, 2004 | 95 | 2004 |
| Delivering natural products and biotherapeutics to improve drug efficacy MA Obeid, MM Al Qaraghuli, M Alsaadi, AR Alzahrani, K Niwasabutra, ... Therapeutic delivery 8 (11), 947-956, 2017 | 94 | 2017 |
| Lipid-based nanoparticles for cancer treatment MA Obeid, RJ Tate, AB Mullen, VA Ferro Lipid nanocarriers for drug targeting, 313-359, 2018 | 81 | 2018 |
| The effects of hydration media on the characteristics of non-ionic surfactant vesicles (NISV) prepared by microfluidics MA Obeid, I Khadra, AB Mullen, RJ Tate, VA Ferro International journal of pharmaceutics 516 (1-2), 52-60, 2017 | 66 | 2017 |
| Chemical and antimicrobial profiling of propolis from different regions within Libya W Siheri, T Zhang, GU Ebiloma, M Biddau, N Woods, MY Hussain, ... Plos one 11 (5), e0155355, 2016 | 66 | 2016 |
| Antibody-protein binding and conformational changes: identifying allosteric signalling pathways to engineer a better effector response MM Al Qaraghuli, K Kubiak-Ossowska, VA Ferro, PA Mulheran Scientific reports 10 (1), 13696, 2020 | 65 | 2020 |
| Efficacy of an anti-fertility vaccine based on mammalian gonadotrophin releasing hormone (GnRH-I)—a histological comparison in male animals VA Ferro, MAH Khan, D McAdam, A Colston, E Aughey, AB Mullen, ... Veterinary immunology and immunopathology 101 (1-2), 73-86, 2004 | 62 | 2004 |
| Immunisation with a plasmid DNA vaccine encoding gonadotrophin releasing hormone (GnRH-I) and T-helper epitopes in saline suppresses rodent fertility MAH Khan, K Ogita, VA Ferro, K Kumasawa, T Tsutsui, T Kimura Vaccine 26 (10), 1365-1374, 2008 | 53 | 2008 |
| Formulation of nonionic surfactant vesicles (NISV) prepared by microfluidics for therapeutic delivery of siRNA into cancer cells MA Obeid, A Elburi, LC Young, AB Mullen, RJ Tate, VA Ferro Molecular pharmaceutics 14 (7), 2450-2458, 2017 | 52 | 2017 |
| Optimizing efficacy of mucosal vaccines A Gebril, M Alsaadi, R Acevedo, AB Mullen, VA Ferro Expert review of vaccines 11 (9), 1139-1155, 2012 | 49 | 2012 |
John Ogbaji IgoliProfessor, Joseph Sarwuan Tarka University, Makurdi, NigeriaVerified email at uam.edu.ng
